H5N8
Ngày Đăng : 2026-11-20 / View: 5
The results show that the vaccine effectively protects most strains of avian influenza in Vietnam, H5N1, H5N6 and H5N8.
Many provinces and cities in our country in recent months have continuously had outbreaks of avian influenza. The results of the analysis of the veterinary samples showed that most of the poultry and waterfowl were infected with the new virus H5N8, there is currently no vaccine licensed for circulation in Vietnam.
Therefore, the import and circulation of new generation avian influenza vaccines with high protection against influenza virus strains A/H5N8 is an urgent requirement from the domestic livestock industry.
In a timely and effective way with domestic poultry farmers, Amavet Veterinary Medicine Trading Joint Stock Company has pioneered in importing the new generation H5 avian influenza vaccine produced by CBM to Vietnam.
After going through the entire import process, testing, analysis, testing and toxicity testing according to the Law on Veterinary Medicine and current regulations, the results show that the batches of chickens are vaccinated with H5 avian influenza vaccine by Amavet. imported have high protective effect, against avian influenza virus branches such as: H5N8 clade 2.3.4.4b; H5N6 clade 2.3.4.4h1; H5N6 clade 2.3.4.4h2; H5N6 clade 2.3.4.4h3; H5N1 clade 2.3.2.1c.
In addition to using newly emerged avian influenza virus strains such as H5N8, H5N6, the H5 vaccine test also confirmed its high effectiveness on the virus strain circulating in Vietnam in the past, the subtype H5N1. The virus used in the test belongs to clade 2.3.2.1c isolated from the 2019 outbreak (A/ck/VN/NgheAn/NCVD-19A31/2019/H5N1).
The results of post-infection monitoring showed that the group of chickens vaccinated with H5 vaccine were not infected, had no clinical symptoms, and no chickens died after being infected with the H5N1 virus clade 2.3.2.1c.
Meanwhile, the control group of chickens died 100% after 5 days of infection with the same virus. Thus, when challenged virulently with the H5N1 virus clade 2.3.2.1c, the H5 vaccine achieved the highest criterion of clinical protective efficacy.
When using a trial of H5 vaccine with a 1-shot course in 3-week-old chickens, it once again showed that products manufactured by Guangzhou South China Biological Medicine Co., LTD (CBM) all responded to the immune response with antibody titers. achieved 5.2 log2 with H5N6 clade 2.3.4.4h1 antigen.
In particular, testing of virus shedding in oropharyngeal swabs at 10 days after infection showed that none of the chickens shed virus (Ct > 35). While the control chickens excrete a lot. Thus, it can be confirmed that H5 vaccine has a very clear effect in reducing the amount of virus shedding when compared between vaccinated and non-vaccinated chickens.

